These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 19340297)

  • 1. CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells.
    Yang X; Karuturi RK; Sun F; Aau M; Yu K; Shao R; Miller LD; Tan PB; Yu Q
    PLoS One; 2009; 4(4):e5011. PubMed ID: 19340297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen-mediated epigenetic repression of the imprinted gene cyclin-dependent kinase inhibitor 1C in breast cancer cells.
    Rodriguez BA; Weng YI; Liu TM; Zuo T; Hsu PY; Lin CH; Cheng AL; Cui H; Yan PS; Huang TH
    Carcinogenesis; 2011 Jun; 32(6):812-21. PubMed ID: 21304052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
    Ren G; Baritaki S; Marathe H; Feng J; Park S; Beach S; Bazeley PS; Beshir AB; Fenteany G; Mehra R; Daignault S; Al-Mulla F; Keller E; Bonavida B; de la Serna I; Yeung KC
    Cancer Res; 2012 Jun; 72(12):3091-104. PubMed ID: 22505648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells.
    Sun F; Chan E; Wu Z; Yang X; Marquez VE; Yu Q
    Mol Cancer Ther; 2009 Dec; 8(12):3191-202. PubMed ID: 19934278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter.
    Qiu Z; Zhu W; Meng H; Tong L; Li X; Luo P; Yi L; Zhang X; Guo L; Wei T; Zhang J
    Theranostics; 2019; 9(16):4717-4729. PubMed ID: 31367252
    [No Abstract]   [Full Text] [Related]  

  • 6. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation.
    Kondo Y; Shen L; Cheng AS; Ahmed S; Boumber Y; Charo C; Yamochi T; Urano T; Furukawa K; Kwabi-Addo B; Gold DL; Sekido Y; Huang TH; Issa JP
    Nat Genet; 2008 Jun; 40(6):741-50. PubMed ID: 18488029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long noncoding RNA TALNEC2 plays an oncogenic role in breast cancer by binding to EZH2 to target p57
    Qiao E; Chen D; Li Q; Feng W; Yu X; Zhang X; Xia L; Jin J; Yang H
    J Cell Biochem; 2019 Mar; 120(3):3978-3988. PubMed ID: 30378143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cross-talk between DNA methylation and H3 lysine 9 dimethylation at the KvDMR1 region controls the induction of Cdkn1c in muscle cells.
    Andresini O; Ciotti A; Rossi MN; Battistelli C; Carbone M; Maione R
    Epigenetics; 2016 Nov; 11(11):791-803. PubMed ID: 27611768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
    Au SL; Wong CC; Lee JM; Wong CM; Ng IO
    PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2 methyltransferase and H3K27 methylation in breast cancer.
    Yoo KH; Hennighausen L
    Int J Biol Sci; 2012; 8(1):59-65. PubMed ID: 22211105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repression of E-cadherin by the polycomb group protein EZH2 in cancer.
    Cao Q; Yu J; Dhanasekaran SM; Kim JH; Mani RS; Tomlins SA; Mehra R; Laxman B; Cao X; Yu J; Kleer CG; Varambally S; Chinnaiyan AM
    Oncogene; 2008 Dec; 27(58):7274-84. PubMed ID: 18806826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
    Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
    Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
    Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation.
    Fujii S; Ito K; Ito Y; Ochiai A
    J Biol Chem; 2008 Jun; 283(25):17324-32. PubMed ID: 18430739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
    Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
    Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic repression of SATB1 by polycomb group protein EZH2 in epithelial cells.
    Lei L; Lu L; Xiang L; Xue-song W; De-pei L; Chih-chuan L
    Chin Med Sci J; 2010 Dec; 25(4):199-205. PubMed ID: 21232178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2.
    Chen S; Bohrer LR; Rai AN; Pan Y; Gan L; Zhou X; Bagchi A; Simon JA; Huang H
    Nat Cell Biol; 2010 Nov; 12(11):1108-14. PubMed ID: 20935635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer.
    Chen H; Tu SW; Hsieh JT
    J Biol Chem; 2005 Jun; 280(23):22437-44. PubMed ID: 15817459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes.
    Fujii S; Tokita K; Wada N; Ito K; Yamauchi C; Ito Y; Ochiai A
    Oncogene; 2011 Sep; 30(39):4118-28. PubMed ID: 21499305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer.
    Pietersen AM; Horlings HM; Hauptmann M; Langerød A; Ajouaou A; Cornelissen-Steijger P; Wessels LF; Jonkers J; van de Vijver MJ; van Lohuizen M
    Breast Cancer Res; 2008; 10(6):R109. PubMed ID: 19099573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.